To include your compound in the COVID-19 Resource Center, submit it here.

Building adVANTage

How Roivant plans to deploy its record $1.1 billion private equity financing

Roivant Sciences GmbH aims to use the largest-ever equity financing into a private biotech to accelerate the addition of new programs to its family of companies and expand into enabling technologies that can improve the quality and efficiency

Read the full 385 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers